EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Belatacept in Kidney Transplantation: Reflecting on the Past, Shaping the Future

Johan Noble, Juliette Leon, Arnaud Del Bello, Dany Anglicheau, Gilles Blancho, Simon Ville, Lionel Couzi, Philippe Grimbert, Yannick Le Meur, Bruno Moulin, Nassim Kamar, Lionel Rostaing und 3 weitere

Transplant International · 20.05.2025 · 38

DOI: 10.3389/ti.2025.14412 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Transplant International, online erschienen am 20.05.2025. Verfasst von Johan Noble und 14 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology, Hemodialysis, Apheresis and Transplantation, Centre Hospitalier Universitaire (CHU) Grenoble-Alpes, La Tronche, France. Hauptthemen laut MEDLINE: Abatacept, Kidney Transplantation, Immunosuppressive Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Calcineurin inhibitors (CNIs) are a cornerstone of post-transplant immunosuppressive regimens. However, their use is associated with adverse effects, most notably chronic nephrotoxicity, which remains a leading cause of long-term allograft dysfunction. Belatacept, a selective costimulation blocker, offers a promising alternative to CNIs by aiming to reduce nephrotoxicity while maintaining efficacy in preventing acute rejection. While its use in de novo transplantation has been associated with improved graft and patient survival, it has also been linked to a higher incidence of acute rejection. Early post-transplantation conversion to belatacept has demonstrated significant improvements in renal function (eGFR gains ranging from +8.8 to +38.2 mL/min/1.73 m 2 at 1 year post-conversion) but carries a higher risk of opportunistic infections. Late conversion protocols, typically initiated beyond 6 months post-transplantation, have shown sustained—although less pronounced—eGFR improvements and better long-term graft survival compared to CNI-based regimens. Additionally, belatacept appears to reduce the incidence of donor-specific antibodies. Future directions for the use of belatacept need further exploration, including its role in rescuing poor renal function, its combination with low-dose CNIs, mTOR inhibitors, or tocilizumab, and its application in desensitization protocols. By potentially striking a balance between efficacy and safety, belatacept may redefine the future landscape of transplant immunosuppression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AbataceptKidney TransplantationImmunosuppressive AgentsHumansGraft RejectionGraft SurvivalCalcineurin Inhibitors

Stichwörter der Autor:innen

belataceptdonor-specific antibodieseGFRkidney transplantationopportunistic infections

Substanzen

AbataceptImmunosuppressive AgentsCalcineurin Inhibitors

Autor:innen und Institutionen

  • Nephrology, Hemodialysis, Apheresis and Transplantation, Centre Hospitalier Universitaire (CHU) Grenoble-Alpes, La Tronche, France.
  • University Grenoble Alpes, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire (CHU) Grenoble Alpes, Institute for Ad…
  • Service des Maladies du Rein et du Métabolisme, Transplantation et Immunologie Clinique, Hôpital Necker, Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France.
  • Département de Néphrologie et Transplantation d'Organes, Centre Hospitalier Universitaire (CHU) Toulouse, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 1291, Toulouse Institute for Infectious an…
  • Service de Néphrologie - Immunologie Clinique, Centre Hospitalier Universitaire (CHU) Nantes, Nantes Université, Nantes, France.
  • Institut de la Transplantation Urologie-Néphrologie (ITUN), Institut National de la Santé et de la Recherche Médicale (INSERM), Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, Fran…

Zitieren

APA

Noble, J., Leon, J., Del Bello, A., Anglicheau, D., Blancho, G., Ville, S., Couzi, L., Grimbert, P., Le Meur, Y., Moulin, B., Kamar, N., Rostaing, L., Herr, F., Durrbach, A., & Bertrand, D. (2025). Belatacept in Kidney Transplantation: Reflecting on the Past, Shaping the Future. Transplant International, 38. https://doi.org/10.3389/ti.2025.14412

Vancouver

Noble J, Leon J, Del Bello A, Anglicheau D, Blancho G, Ville S, et al. Belatacept in Kidney Transplantation: Reflecting on the Past, Shaping the Future. Transplant International. 2025;38. doi:10.3389/ti.2025.14412

BibTeX
@article{Noble2025,
  author = {Noble, Johan and Leon, Juliette and Del Bello, Arnaud and Anglicheau, Dany and Blancho, Gilles and Ville, Simon and Couzi, Lionel and Grimbert, Philippe and Le Meur, Yannick and Moulin, Bruno and Kamar, Nassim and Rostaing, Lionel and Herr, Florence and Durrbach, Antoine and Bertrand, Dominique},
  title = {Belatacept in Kidney Transplantation: Reflecting on the Past, Shaping the Future},
  journal = {Transplant International},
  year = {2025},
  volume = {38},
  doi = {10.3389/ti.2025.14412}
}
Kostenlos starten →